Takeda Pharmaceutical (TAK) Other financing activities (2018 - 2020)

Takeda Pharmaceutical has reported Other financing activities for 3 years, with the latest figure at $34.2 million in Q1 2020.

• On a quarterly basis, Other financing activities fell 81.78% year-over-year to $34.2 million in Q1 2020; TTM through Mar 2020 was $187.3 million, a 5.75% increase from a year earlier, with the FY2019 full-year figure at $177.2 million, changed N/A from the prior year.
• Other financing activities was $34.2 million for Q1 2020 at Takeda Pharmaceutical, up from -$34.7 million in the prior quarter.
• The five-year high for Other financing activities was $187.8 million in Q1 2019, with the low at -$34.7 million in Q3 2019.
• Average Other financing activities over 3 years is $43.7 million, with a median of -$36080.6 recorded in 2018.
• The largest YoY upside for Other financing activities was 99.74% in 2019 against a maximum downside of 77168.18% in 2019.
• Over 3 years, Other financing activities stood at -$53196.0 in 2018, then plunged by 65087.44% to -$34.7 million in 2019, then jumped by 198.66% to $34.2 million in 2020.
• The last three Other financing activities figures came in at $34.2 million (Q1 2020), -$34.7 million (Q3 2019), and -$27282.3 (Q2 2019), per Business Quant data.